Develops medicines for cancer, cardiovascular and neurodegenerative diseases, including generic drugs, biosimilars and Klotho gene therapies. Also develops and mines critical and precious minerals.
10-K for FY2025, filed Apr 1, 2026
No revenue reported yet.
10-K for FY2025, filed Apr 1, 2026
10-Q for Q2 FY2026, filed Aug 17, 2026
−$3.7MView ↗
8-K, filed Sep 4, 2026
Item 2.01 – Completion of Acquisition or Disposition of AssetsView ↗
8-K, filed Jun 29, 2026
Greenland Mines Ltd. (the “Company”), was notified that Simon & Edward LLP (“S&E”) acquired, effective as of June 15, 2026, attest business…View ↗
From blank-check company to operating businesses
The older report describes a blank-check company seeking a business combination, focused on carbon-neutral and energy-storage industries. The latest report describes medicine development and an acquisition that expands operations into critical- and precious-mineral development and mining.
10-K for FY2022, filed Apr 10, 2023 10-K for FY2025, filed Apr 1, 2026We are a blank check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, share exchange, asset…View ↗
Competes with Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Biogen, AstraZeneca, Teva Pharmaceutical Industries, Klothea BIO, Klotho Therapeutics, Klogenix, Amgen, Celltrion Healthcare, Sandoz International, Unity Biotechnology, Jocasta Therapeutics, Mylan, and Reliance Life Sciences
10-K for FY2025, filed Apr 1, 2026There are three classes of drugs that are used to help with the physiologic effects of advancing cognitive disorders and dementia, (1)…View ↗
Loading...